BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18483350)

  • 1. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
    Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
    BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
    Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
    Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases.
    Zafeirakis AG; Papatheodorou GA; Limouris GS
    Nucl Med Commun; 2010 Mar; 31(3):249-53. PubMed ID: 20038858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
    Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
    Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
    Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
    Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
    Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
    Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
    Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
    J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
    Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
    Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.